GSK Type 1 Diabetes Drug Does Not Make It in Phase III Clinical Trials

by Savitha C Muppala on  March 13, 2011 at 2:37 PM Clinical Trials News
RSS Email Print This Page Comment
Font : A-A+

A Type 1 diabetes drug developed by London-based GlaxoSmithKline and Cambridge, Massachusetts-based Tolerx, was not successful in the phase III clinical trials.
 GSK Type 1 Diabetes Drug Does Not Make It in Phase III Clinical Trials
GSK Type 1 Diabetes Drug Does Not Make It in Phase III Clinical Trials

Explaining their commitment to the clinical development of type 1 diabetes drug, Jackie Parkin, GSK's medicines development leader, said, "Clearly these are disappointing data, but we are committed to working with Tolerx to better understand the results of this study and determine the way forward."



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Diabetic Retinopathy Drug Toxicity Diabetes Diabetic Diet Otitis Media Clinical Trials Diabetes - Essentials Clinical Trials - The Past and The Future Clinical Trials - Different Phases of the trial Diabetes - Self-Monitoring of Blood Glucose (SMBG) 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive